0000014272-20-000040.txt : 20200115
0000014272-20-000040.hdr.sgml : 20200115
20200115170435
ACCESSION NUMBER: 0000014272-20-000040
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191231
FILED AS OF DATE: 20200115
DATE AS OF CHANGE: 20200115
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: VESSEY RUPERT
CENTRAL INDEX KEY: 0001677618
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-01136
FILM NUMBER: 20528798
MAIL ADDRESS:
STREET 1: C/O CELGENE CORPORATION
STREET 2: 86 MORRIS AVENUE
CITY: SUMMIT
STATE: NJ
ZIP: 07901
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BRISTOL MYERS SQUIBB CO
CENTRAL INDEX KEY: 0000014272
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 220790350
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 430 E. 29TH STREET
STREET 2: 14 FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10016
BUSINESS PHONE: 2125464000
MAIL ADDRESS:
STREET 1: 430 E. 29TH STREET
STREET 2: 14 FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10016
FORMER COMPANY:
FORMER CONFORMED NAME: BRISTOL MYERS CO
DATE OF NAME CHANGE: 19891012
4/A
1
wf-form4a_157912585811970.xml
FORM 4/A
X0306
4/A
2019-12-31
2020-01-03
0
0000014272
BRISTOL MYERS SQUIBB CO
BMY
0001677618
VESSEY RUPERT
430 E. 29TH STREET
14TH FLOOR
NEW YORK
NY
10016
0
1
0
0
Pres., Research & Early Dev.
Common Stock, $0.10 par value
2019-12-31
4
M
0
16060
0
A
30238
D
Common Stock, $0.10 par value
2019-12-31
4
F
0
7910
64.19
D
22328
D
Common Stock, $0.10 par value
613
I
401(k)
In connection with the merger, all outstanding Celgene Corporation (Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award.
The restricted stock unit vests in full on December 31, 2019, which is the end of the original performance period associated with the original Performance Share Unit award.
Due to an administrative error, this Form 4 is being amended to report in Column 5 the correct number of securities beneficially owned following the reported transaction.
Shares withheld for payment of taxes upon vesting of awards.
Based on a plan statement as of the end of the third quarter.
/s/ Lisa A. Atkins, attorney-in-fact for Rupert Vessey
2020-01-14